CLLS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cellectis SA (CLLS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has a strong analyst rating with a price target significantly higher than the current price, positive technical indicators, and promising developments in its CAR-T product pipeline. Despite the lack of recent news or financial data, the stock's current price and technical setup present a solid entry point for long-term growth potential.
The MACD histogram is positive at 0.063, showing bullish momentum. The RSI is neutral at 55.575, indicating no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading above key support levels (Pivot: 3.883, S1: 3.558). Resistance levels are at R1: 4.208 and R2: 4.408, suggesting room for upward movement.
Analyst Bill Maughan initiated coverage with a Buy rating and a $9 price target, citing strong efficacy data from Cellectis' CAR-T programs.
Bullish technical indicators, including positive MACD and moving averages.
High implied volatility percentile (84.86), indicating potential for significant price movement.
Lack of recent news or financial performance data to further validate the investment.
No significant hedge fund or insider trading activity, suggesting neutral sentiment from key stakeholders.
No financial data available for the latest quarter, but the market cap is $404.38M, and the company is expected to report Q4 2025 earnings on March 12, 2026.
Clear Street analyst Bill Maughan initiated coverage with a Buy rating and a $9 price target, highlighting strong efficacy data from Cellectis' CAR-T programs in hematological cancers.
